

Corp. Reg. No. 556756-8521
Date: June 2, 2020

Idogen has been approved for listing on Nasdaq First North Growth Market

Idogen AB ("Idogen" or the "Company") has today received approval for admission to trading on Nasdaq First North Growth market. First day of trading on Nasdaq First North Growth Market is on Thursday, June 4, 2020.

Nasdaq Stockholm has today announced that Idogen fulfills the listing requirements on Nasdaq First North Growth Market and the Company has received approval for admission to trading on Nasdaq First North Growth Market. The first day of trading on Nasdaq First North Growth Market is on Thursday, June 4, 2020. Idogen has previously been listed on the Spotlight Stock Market and the last day for trading on Spotlight Stock Market is on Wednesday, June 3, 2020. In connection with the listing on the Nasdaq First North Growth Market, Idogen has appointed Erik Penser Bank as the Company's Certified Adviser.

The Idogen share will continue to trade with ISIN code SE0014428561 and under the ticker IDOGEN. The Company's shareholders do not need to take any measures in connection with the change of listing venue.

For further information, please contact:

Anders Karlsson, CEO, Idogen AB

Tel: +46 70 918 00 10

E-mail: anders.karlsson@idogen.com

The information was submitted for publication, through the agency of the contact persons set out above, on June 2, 2020.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced project, IDO 8, is designed to restore the efficacy of haemophilia drugs in patients who have developed neutralizing antibodies. The company's second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.